Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Twist Bioscience Corp (TWST) reported an insider transaction by Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary. On June 20, 2025, Cho executed a mandatory "sell to cover" transaction involving 230 shares of common stock at a price of $35.755 per share.
The sale was specifically conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) and was not a discretionary trade. Following the transaction, Cho maintains direct beneficial ownership of 104,737 shares of common stock.
This transaction was executed under the company's equity incentive plan requirements, which mandate the satisfaction of tax withholding obligations through "sell to cover" transactions. The Form 4 was filed on June 28, 2025, with the signature of Kendra Fox acting as Attorney-in-Fact for Dennis Cho.
Form 144 filing for Twist Bioscience Corporation (TWST) discloses a proposed sale of 292 common shares by insider Paula Green through Fidelity Brokerage Services on or about 06/20/2025. The shares have an aggregate market value of $10,440.37, versus 59,916,141 shares outstanding, representing roughly 0.0005% of the float—an immaterial amount for public investors.
During the preceding three months, the same seller completed five sales totaling 3,017 shares for combined gross proceeds of $104,886.82. All shares being sold were acquired via restricted-stock vesting on 06/18/2025 and are being disposed of for compensation purposes. The filer attests that no undisclosed material adverse information is known.
The filing is routine, signals no change to corporate fundamentals, and appears unlikely to influence TWST’s valuation or liquidity.
Form 4 overview: On 06/16/2025, Twist Bioscience Corporation (TWST) officer Dennis Cho executed a mandatory “sell-to-cover” transaction, disposing of 94 common shares at $33.475 per share to satisfy tax-withholding obligations arising from vested Restricted Stock Units. This was not a discretionary trade under Rule 10b5-1.
After the sale, Cho continues to beneficially own 104,967 TWST shares and remains Senior Vice President, Chief Legal Officer & Corporate Secretary. The divestiture represents well under 0.1 % of his holdings, leaving insider ownership essentially unchanged and providing limited informational value for investors.